Basel, Switzerland-based Roche Holding Ltd. is a leading healthcare company focused on developing and commercializing innovative drugs and diagnostic products and services, which enable the early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments — Pharmaceuticals and Diagnostics.
Pharmaceuticals: Key focus areas in this segment are Oncology, Virology, Inflammation, Metabolism and Neuroscience. The segment accounted for 76% of total sales in 2023.
Diagnostics: The Diagnostics Division operates under five segments — Core Lab, Molecular Lab, Pathology Lab, Point ...
Basel, Switzerland-based Roche Holding Ltd. is a leading healthcare company focused on developing and commercializing innovative drugs and diagnostic products and services, which enable the early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments — Pharmaceuticals and Diagnostics.
Pharmaceuticals: Key focus areas in this segment are Oncology, Virology, Inflammation, Metabolism and Neuroscience. The segment accounted for 76% of total sales in 2023.
Diagnostics: The Diagnostics Division operates under five segments — Core Lab, Molecular Lab, Pathology Lab, Point of Care and Diabetes Care. The segment accounted for 24% of total sales in 2023.
Roche has been active on the acquisition front to expand its portfolio. In July 2018, Roche company acquired Foundation Medicine Inc. to broaden its healthcare portfolio and aims to advance further molecular insights and the broad availability of high-quality, comprehensive genomic profiling, both key enablers for the development of new cancer treatments and optimal patient care. Roche’s subsidiary, Genentech, also obtained full rights to Jecure’s entire preclinical portfolio of NLRP3 inhibitors. In December 2019, Roche acquired Spark Therapeutics, Inc. In 2023, Roche acquired Telavant, including rights to the novel TL1A-directed antibody (RVT-3101) from Roivant for the treatment of inflammatory bowel disease.
In January 2024, Roche acquired Carmot Therapeutics and gained three clinical-stage assets with best-in-class potential in obesity (CT-388 and CT-996) and diabetes (CT-868) in its portfolio.
Sales for 2023 came in at CHF 58.7 billion, down 7% from the 2022 level.